Pharmaceutical compound
 | |
| Clinical data | |
|---|---|
| Trade names | Hytrin, Zayasel, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a693046 |
| License data | |
| Routes of administration | By mouth |
| Drug class | α1 blocker |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | 90–94% |
| Elimination half-life | 12 hours |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.118.191  |
| Chemical and physical data | |
| Formula | C19H25N5O4 |
| Molar mass | 387.440 g·mol |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (verify) | |
Terazosin, sold under the brand name Hytrin among others, is a medication used to treat symptoms of an enlarged prostate and high blood pressure. For high blood pressure, it is a less preferred option. It is taken by mouth.
Common side effects include dizziness, headache, feeling tired, swelling, nausea, and low blood pressure with standing. Severe side effects may include priapism and low blood pressure. Prostate cancer should be ruled out before starting treatment. It is an alpha-1 blocker and works by relaxing blood vessels and the opening of the bladder.
Terazosin was patented in 1975 and came into medical use in 1985. It is available as a generic medication. In 2021, it was the 234th most commonly prescribed medication in the United States, with more than 1 million prescriptions.
Synthesis
Reaction of piperazine with 2-furoyl chloride followed by catalytic hydrogenation of the furan ring leads to 2. This, when heated in the presence of 2-chloro-6,7-dimethoxyquinazolin-4-amine (1) undergoes direct alkylation to terazosin (3).
Research on neuroprotective effects
A 2022 study suggests that terazosin may have the potential to confer neuroprotection upon motor neurons in motor neuron disease, as a result of its ability to activate PGK1.
References
- ^ "Terazosin Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 17 March 2019.
- Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 455. ISBN 9783527607495.
- British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 768. ISBN 9780857113382.
- "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
- "Terazosin - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
- US 4026894, Winn M, Kyncl J, Dunnigan DA, Jones PH, issued 31 May 1977, assigned to Abbott
- Chaytow H, Carroll E, Gordon D, Huang YT, van der Hoorn D, Smith HL, et al. (September 2022). "Targeting phosphoglycerate kinase 1 with terazosin improves motor neuron phenotypes in multiple models of amyotrophic lateral sclerosis". eBioMedicine. 83: 104202. doi:10.1016/j.ebiom.2022.104202. PMC 9482929. PMID 35963713.
| Drugs used in benign prostatic hyperplasia (G04C) | |
|---|---|
| 5α-Reductase inhibitors | |
| Alpha-1 blockers | |
| Steroidal antiandrogens | |
| Herbal products | |
| Others | |
